Laekna Therapeutics will present two clinical study results in ESMO 2021

Laekna Therapeutics will present two clinical study results in ESMO 2021
News provided by
Share this article
Share this article
SHANGHAI and WARREN, N.J., July 26, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging innovative pharma company based in China's "Zhangjiang Pharma Valley" and New Jersey in the U.S. and focused on developing new groundbreaking innovative therapies to treat cancer and liver diseases, announced today that it will present the results from two clinical studies on the treatment of prostate cancer at the European Society for Medical Oncology (ESMO) Congress 2021.
ePoster
Presentation Number: 597P
This
ClinicalTrials NCT03843918 is a phase I monotherapy dose-escalation study of LAE001, in patients with metastatic castration-resistant prostate cancer (mCRPC).  LAE001 is the first CYP17/CYP11B2 dual inhibitor globally. It is a novel, potent, non-steroidal, reversible dual inhibitor of CYP17 and CYP11B2 (aldosterone synthase) that blocks both androgen and aldosterone synthesis, Therefore, unlike abiraterone acetate, LAE001 does not need a co-medication of prednisone. Laekna plan to further develop LAE001 to treat patients with mCSPC, who usually have a much longer treatment duration, and would benefit more from using LAE001.

Related Keywords

China ,Shanghai ,United States ,New Jersey ,Dingwei ,Fujian ,America ,Cleo Zhang ,Leah Liu ,Alberto Bessudo Encinitas ,European Society For Medical Oncology ,Novartis ,European Society ,Medical Oncology ,Phasei Dose Escalation Study ,Prednisone Plus Afuresertib ,Metastatic Castration Resistant Prostate Cancer ,Following Standard ,Alberto Bessudo ,Central European Summertime ,Laekna Therapeutics ,சீனா ,ஷாங்காய் ,ஒன்றுபட்டது மாநிலங்களில் ,புதியது ஜெர்சி ,புஜியன் ,அமெரிக்கா ,கிளியோ ஜாங் ,லியா லியூ ,ஐரோப்பிய சமூகம் க்கு மருத்துவ புற்றுநோயியல் ,நோவர்த்திச் ,ஐரோப்பிய சமூகம் ,மருத்துவ புற்றுநோயியல் ,மெட்டாஸ்டேடிக் வார்ப்பு எதிர்ப்பு ப்ராஸ்டேட் புற்றுநோய் ,